Bevacizumab biosimilar - Beijing Eastern Biotech
Alternative Names: JY028Latest Information Update: 28 Dec 2022
At a glance
- Originator Beijing Eastern Biotech
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Wet age-related macular degeneration
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)
- 28 Jun 2021 No recent reports of development identified for phase-I development in Wet age-related macular degeneration in China (Intravitreous, Injection)
- 01 Jul 2020 Shanghai Public Health Clinical Center initiates enrolment in a phase I trial In volunteers (ChiCTR2000035350)